



MEDICAL TIPS

DIABIZ TABLETS

Issue IV, No. 15, 2022

Long-term effectiveness and safety of quadruple combination therapy with empagliflozin versus dapagliflozin in patients with type 2 diabetes: 3-year prospective observational study

Ku EJ et al. Diabetes Res Clin Pract 2021; 182: 109123.

- A study was conducted to investigate the long-term effectiveness and safety of adding empagliflozin or dapagliflozin, in inadequately controlled T2DM despite a triple drug regimen of metformin, glimepiride and a DPP-4 inhibitor.
- 362 patients were administered an added dapagliflozin or empagliflozin along with their existing triple drug regimen.
- HbA1c, fasting plasma glucose (FPG), body weight, and other cardiometabolic variables and adverse events were evaluated at baseline and end of 3 years.
- There were significant reductions in the parameters with dapagliflozin and empagliflozin.

Quadruple combination therapy with dapagliflozin showed a positive long-term effect in the glycaemic control and body weight reduction with generally well tolerance.

